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The homeobox factor PDX-1 is a key regulator of pancreatic
morphogenesis and glucose homeostasis; targeted disruption of
the PDX-1 gene leads to pancreatic agenesis in pdx-1(2y2) ho-
mozygotes. Pdx-1 heterozygotes develop normally, but they dis-
play glucose intolerance in adulthood. Like certain other ho-
meobox proteins, PDX-1 contains a consensus FPWMK motif that
promotes heterodimer formation with the ubiquitous homeodo-
main protein PBX. To evaluate the importance of PDX-1:PBX com-
plexes in pancreatic morphogenesis and glucose homeostasis, we
expressed either wild-type or PBX interaction defective PDX-1
transgenes under control of the PDX-1 promoter. Both wild-type
and mutant PDX-1 transgenes corrected glucose intolerance in
pdx-1 heterozygotes. The wild-type PDX-1 transgene rescued the
development of all pancreatic lineages in pdx-1(2y2) animals, and
these mice survived to adulthood. In contrast, pancreata from
pdx-1(2y2) mice expressing the mutant PDX-1 transgene were
hypoplastic, and these mice died within 3 weeks of birth from
pancreatic insufficiency. All pancreatic cell types were observed in
pdx-1(2y2) mice expressing the mutant PDX-1 transgene; but the
islets were smaller, and increased numbers of islet hormone-
positive cells were noted within the ductal epithelium. These
results indicate that PDX-1:PBX complexes are dispensable for
glucose homeostasis and for differentiation of stem cells into
ductal, endocrine, and acinar lineages; but they are essential for
expansion of these populations during development.
The homeobox protein PDX-1 functions critically in pancreaticdevelopment and glucose homeostasis; murine and human
pdx-1(2y2) homozygotes are apancreatic (1–3), and pdx-1 het-
erozygotes develop glucose intolerance in adulthood, partly be-
cause of inadequate insulin gene expression (4, 5). Further under-
scoring the importance of this factor for glucose homeostasis,
mutations in the PDX-1 gene have been identified in patients with
maturity onset diabetes of the young-type 4 (6). Consistent with this
phenotype, PDX-1 stimulates the expression of certain islet-specific
genes such as somatostatin (7, 8), insulin (9–11), glut-2 (12), and
glucokinase (13), by binding as a monomer to promoter sites that
contain a GTAATC consensus site.
Like certain homeobox factors, PDX-1 also binds as a het-
erodimer with the ubiquitous homeodomain protein PBX to target
sites containing a consensus TGATTAAT motif. Detected in crude
extracts from insulinoma cells (14), PDX-1:PBX complexes have
also been observed in ductal and acinar cell lines, where they
regulate the expression of exocrine target genes such as elastase
(15). Compared with the PDX-1 monomer, the PDX-1:PBX het-
erodimer binds with 10- to 20-fold higher affinity to its sites (14),
suggesting a potential mechanism by which PDX-1 target genes are
hierarchically regulated during development.
To examine the requirement for PDX-1:PBX complexes in
pancreatic morphogenesis, islet cell differentiation, and glucose
homeostasis, we developed transgenic mice expressing either
wild-type or PBX interaction defective PDX-1 transgenes under
control of the PDX-1 promoteryenhancer. In the context of a
pdx-1(2y2) background, the wild-type PDX-1 transgene com-
pletely rescued pancreatic development and glucose homeostasis
in adult mice. The mutant PDX-1 transgene also corrected
glucose intolerance in pdx-1(1y2) mice, but it was unable to
fully rescue pancreatic development in pdx-1(2y2) animals. All
cell types within the pancreas of pdx-1(2y2) mice expressing the
mutant PDX-1 transgene were present; but their organization
and overall proliferation were greatly affected. These results
show that PDX-1:PBX complexes are dispensable for the gen-
eration of the various cell types within the pancreas, but they are
required for expansion of these cell populations during devel-
opment. Taken together, these studies demonstrate that PDX
monomers and PDX:PBX heterodimers perform distinct func-
tions in the developing pancreas, reflecting in part their capacity
to regulate discrete subsets of pancreatic target genes.
Materials and Methods
Plasmids and Transgenic Mice. Wild-type and mutant PDX-1 trans-
genes were constructed with the use of a 15-kb rat PDX-1 genomic
clone (16) that, in addition to the 1-kb coding region, contains 6.5
kb of 59 flanking sequence, a 4-kb intron, and 3 kb of 39 flanking
sequence. The PBX interaction defective PDX-1 clone contained
mutations in sequences encoding aa 119–123 of the rat PDX-1 gene
(FPWMKyAAGGQ), which were generated by PCR-based mu-
tagenesis (14). Plasmids were injected into C57BL6 mouse oocytes.
Three independent lines of mice expressing the wild-type PDX-1
transgene and two independent lines expressing the mutant PDX-1
transgene were generated. Glucose tolerance tests were performed
as previously described (4).
RNase Protection and Western Blot Assays. RNase protection assays
were performed as previously reported (16), with a 450-base
antisense PDX-1 riboprobe, extending from 1130 to 1530 of the
rat PDX-1 cDNA and containing 50 nucleotides of plasmid
sequence. Western blot assays were performed with the use of
PDX-1-specific antiserum as reported (17).
Immunolabeling. Double immunofluorescence labeling was per-
formed sequentially with primary antibodies made in different
species: guinea pig anti-human insulin (Linco Research Immu-
noassay, St. Charles, MO), rabbit anti-bovine glucagon (kindly
donated by M. Appel, University of Massachusetts Medical
School, Worcester, MA), and rabbit anti-synthetic somatostatin,
a mixture of the three non-b cell hormone antibodies (anti-
glucagon, -somatostatin and -pancreatic polypeptide). Antibod-
ies were used on paraffin sections of 4% buffered formaldehyde-
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fixed pancreas, with the exception of PBX-1 antiserum (Santa
Cruz Biotechnology), which was used on freshly frozen sections
of 3-day-old wild-type mouse pancreas. The secondary antibod-
ies used for immunofluorescence were Texas Red-conjugated
donkey anti-guinea pig IgG, FITC-conjugated donkey anti-
rabbit IgG-, and streptavidin-conjugated FITC (all 1:100 dilu-
tion; Jackson ImmunoResearch). After extensive rinsing, slides
were mounted with DABCO glycerol anti-fading mounting
media. Immunoperoxidase labeling was carried out with the
Histomouse kit (Zymed) for insulin (1:1000) or the Vectastain
ABC kit (Vector Laboratories) for glucagon (1:1000) and so-
matostatin (1:1000). Detection of b-galactosidase from the
pdx-1lacZKO allele was performed as previously described.
Results
Mutagenesis of the PBX interaction motif in PDX-1 (aa 119–
123; FPWMKyAAGGQ) has been shown to block complex
formation with PBX on a heterodimer recognition site (14).
Disruption of this motif in HoxA9 does not eliminate cooper-
ativity with PBX (18), however, prompting us to evaluate
functional interactions between a transcriptionally activated
PBX (E2A-PBX) and wild-type or PBX interaction defective
PDX proteins. Consistent with the selectivity of heterodimer
binding sites for PBX:HOX complexes, wild-type and mutant
PDX-1 proteins alone had marginal activity on a TSEII reporter
that contains two PDX:PBX heterodimer recognition sites (Fig.
1A). After cotransfection with E2A-PBX, the wild-type PDX-1
construct induced reporter activity by 4- to 5-fold (Fig. 1 A). In
contrast, E2A-PBX had no effect on reporter activity in cells
cotransfected with the mutant PDX-1 construct, demonstrating
that disruption of the PBX interaction motif in PDX-1 is indeed
sufficient to block functional cooperativity with PBX.
To evaluate the role of PDX-1:PBX complexes in promoting
pancreatic morphogenesis and glucose homeostasis, we pre-
pared transgenic mice expressing wild-type or PBX interaction
defective PDX-1 proteins under the control of the PDX-1
promoteryenhancer (Fig. 1B). In previous experiments using
lacZ reporter transgenes, both rat and mouse PDX-1 gene
promoteryenhancers have been found to recapitulate the spa-
tiotemporal expression pattern of the endogenous PDX-1 gene
in transgenic mice (16, 19).
When fused to the rat PDX-1 promoteryenhancer, mutant and
wild-type PDX-1 transgenes were comparably expressed in
pancreatic tissue from founder animals by RNase protection and
Western blot assays (Fig. 1C). The size and appearance of the
pancreas in animals carrying mutant (mTg) or wild-type (wtTg)
transgene mice were indistinguishable from nontransgenic lit-
termates (not shown), indicating that neither transgene inter-
feres with normal pancreatic development in this context.
To determine whether PDX-1:PBX complexes are required
for glucose homeostasis, we crossed mTg and wtTg mice with
pdx-1(1y2) mice (1). PDX-1 protein levels in pancreatic ex-
Fig. 1. Expression of wild-type or PBX interaction defective PDX-1 transgenes rescues glucose homeostasis in pdx-1 (1y2) mice. (A) Transient transfection assay
of wild-type and PBX interaction defective (Pdxm) PDX-1 constructs in 293T cells, with a TSEII luciferase reporter containing two PDX:PBX heterodimer recognition
sites. Cells were transfected with wild-type or mutant PDX plus E2A-PBX expression vector where indicated. The first bar on the left represents control transfection
with empty vector alone plus TSEII reporter. Luciferase activity shown after normalizing to b-galactosidase activity from cotransfected RSV-bgal plasmid. (B)
Genotypic analysis of mice expressing PDX-1 transgene. (Left) Inheritance of PDX-1 transgene was evaluated by PCR assay with primers that are selective for rat
PDX-1. (Right) Mice heterozygous or homozygous for targeted disruption of the murine PDX-1 gene were identified by genomic Southern blot analysis with a
32P-labeled PDX-1 cDNA probe. Insertion of the inactivating b-galactosidase gene is indicated by a 3.8-kb vs. a 3.0-kb EcoRI fragment. (C) Wild-type (Lane 1) and
mutant (Lane 2) PDX-1 transgenes are comparably expressed in transgenic mice. (Left) RNase protection assay of total RNA from whole pancreas of adult mice,
with the use of 32P-labeled wild-type PDX-1 antisense RNA probe. The shorter fragment in mutant mice results from RNase digestion in sequences encoding
mutant FPWMKyAAGGQ motif. Lane 3, control nontransgenic littermate RNA; the rat PDX-1 probe does not recognize murine PDX-1. Lane 4, position of
undigested PDX-1 antisense probe. Lane 5, molecular weight marker. (Right) Western blot assay of whole pancreas extract, showing levels of PDX-1 protein in
wild-type, pdx-1(1y2), pdx-1(1y2);mTg, and pdx-1(2y2);wtTg mice. (D) Line graph of blood glucose levels in wild-type (— n —), pdx-1(1y2) heterozygous
(– –}– –), pdx-1(1y2); wtTg, and pdx-1 (1y2);mTg mice (zzzFzzz) after i.p. glucose injection. Results for pdx-1(1y2); wtTg and pdx-1(1y2);mTg mice were
indistinguishable.
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Fig. 2. Islet hypoplasia in pdx-1(2y2);mTg neonates. (A) Comparison of pdx-1(2y2);mTg (smaller) and wild-type (larger) littermates 16 days after birth. (B)
Whole mount of pdx-1(2y2); wtTg and pdx-1(2y2); mTg mice. Ventral (Left) and dorsal (Right) views are included. p, pancreas; d, duodenum; sp, spleen; s,
stomach. (C) Immunocytochemical analysis of insulin (red, arrows) and glucagon 1 somatostatin (green, asterisks) cells in sections from pdx-1(2y2); wtTg (Upper)
and pdx-1(2y2):mTg (Lower). (D) Whole mount showing smaller developing islets (dark blue; arrowheads) in pdx-1(2y2) mTg compared with pdx-1(1y2) mTgt
mice. Blue color indicates expression of b-galactosidase from the endogenous pdx-1 allele pdx-1lacZKO (1).














tracts from pdx-1(1y2) mice were about half that of wild-type
animals by Western blot analysis; and expression of either
wild-type or mutant transgenes restored PDX-1 protein to
wild-type levels in pdx-1 heterozygotes (Fig. 1D). After i.p.
glucose injection, blood glucose levels in wild-type mice rose to
175 mgydl within 15 min, returning to baseline after 2 h. As
expected, blood glucose levels in pdx-1(1y2) mice rose to 350
mgydl after 20 min and remained abnormally elevated for the
duration of the assay (ref. 4; Fig. 1D). Consistent with the notion
that monomeric PDX-1 is sufficient for the activation of genes
involved in glucose homeostasis, expression of either wild-type
or mutant PDX-1 transgenes corrected the impairment in glu-
cose homeostasis in pdx-1 heterozygotes (Fig. 1D). These results
suggest that PDX-1:PBX complexes are dispensable for islet cell
function in the adult.
To determine the importance of PDX-1:PBX complexes in
pancreatic development, we analyzed the activities of wild-type
and mutant PDX-1 transgenes in the context of pdx-1(2y2)
homozygous mice. pdx-1(2y2) mice were apancreatic and died
2–3 days after birth (1, 2); but pdx-1(2y2);wtTg mice developed
normally and survived to adulthood. Mice expressing the mutant
PDX-1 transgene (pdx-1(2y2);mTg) were comparable in size to
nontransgenic mice at birth, but they were noticeably smaller
after 2 weeks and failed to survive past 3 weeks (Fig. 2A).
pdx-1(2y2);wtTg mice had a normal pancreas with a normal
proportion of islet and exocrine cells (Fig. 2 B and C). Compared
with pdx-1(2y2);wtTg mice, the overall size of the pancreas in
pdx-1(2y2);mTg mice at birth was 30–40% of normal, and the
islets were markedly smaller (Fig. 2 B–D).
Each of the cell types evaluated immunocytochemically
(insulin, somatostatin, and glucagon) was present in
Fig. 3. Pancreatic islets of neonatal pdx-1(2y2);mTg mice are smaller and have disrupted architecture. (A–D) Sections of pdx-1(1y2); mTg islets. (E–H) Sections
of pdx-1(2y2); mTg islets. pdx-1(2y2); mTg islets are much smaller and are located in close proximity to the ducts. Immunohistochemistry (brown) shows
insulin-positive (F), glucagon-positive (G), and somatostatin-positive (H) cells in pdx-1(2y2); mTg islets. Glucagon- and somatostatin-positive cells (G and H) are
not localized at the islet periphery as in wild-type islets (compare with C and D).
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pdx-1(2y2);mTg mice; but the distribution of these cells within
individual islets was abnormal (Fig. 3). In particular, glucagon-
and somatostatin-expressing cells were located throughout the
small endocrine clusters and not exclusively at the periphery, as
in wild-type mice (Fig. 3, compare C, D, G, and H).
The reduced size of the pancreas in pdx-1(2y2);mTg mice
prompted us to attempt to determine whether the proliferation
of pancreatic cells was correspondingly lower in these animals.
By using the marker Ki-67 (20) as a reliable index of ongoing
cellular proliferation, we observed intense staining in about
20–30% of pancreatic cells from wild-type newborn animals
(Fig. 4A, Left). Consistent with their relative abundance in the
neonatal pancreas, acinar cells accounted for the highest per-
centage of proliferating cells, followed by ductal and islet cells.
Ki-67 staining was severely reduced in pdx-1(2y2);mTg mice;
both the number and intensity of immunopositive cells were
markedly lower, and all cell types within the pancreas were
equally affected (Fig. 4A, Right). These results suggest that
PDX-1:PBX complexes promote the expansion of various lin-
eages within the pancreas by enhancing cellular proliferation.
To identify particular cell types where PDX-1:PBX complexes
are likely to form, we conducted immunocytochemical studies with
PBX-1 antiserum. PBX-1 was localized in the nucleus in all cells of
the neonatal pancreas; the highest levels of PBX-1 were detected in
ductal cells, with modest to low staining in islets and acinar cells,
respectively (Fig. 4B). These results support the notion that PDX-1
interacts with PBX primarily in ductal epithelial cells, the site of
presumed stem cells and the origin of islet endocrine cells. Re-
markably, pancreatic ducts of pdx-1(2y2);mTg neonates contained
numerous hormone-positive cells (Fig. 4C), whereas wild-type
neonates did not (not shown). Indeed, all major hormone (insulin,
glucagon, somatostatin) cell types were detected, suggesting a
general defect in islet cell migration in these mice (Fig. 4C). Taken
together, these results indicate that the interaction of PDX-1 with
PBX is critical for early events in pancreatic development, including
migration of differentiating endocrine cells or precursors out of the
duct to form proper islets and proliferation of pancreatic cell types.
Discussion
PDX-1 has been shown to stimulate pancreatic gene expression
in vitro, in part, as a heterodimer with PBX (14, 15), although the
functional importance of this complex relative to the PDX-1
monomer has not been appreciated. Our results demonstrate a
differential requirement in vivo for PDX-1:PBX heterodimers
with respect to the initial specification of exocrineyendocrine cell
types and the formation of the normal architecture of the mature
organ.
In the absence of PDX-1, pancreatic development is arrested at
the early bud stage, with complete absence of the major cell types
(proper endocrine, exocrine, or ductal cells; refs. 9–11). Each of
these pancreatic cell types is present, however, in pdx-1(2y2);mTg
neonates, suggesting that monomeric (non-PBX-associated)
PDX-1 activity is sufficient to promote initiation of a complete
pancreatic genetic program. PDX-1:PBX complexes were also
Fig. 4. Pancreata from pdx-1 (2y2);mTgt mice show a defect in proliferation and contain increased numbers of hormone-positive cells in the ductal epithelium.
(A) Immunocytochemical staining of whole-pancreas sections from pdx-1 (2y2);wtTg and pdx-1 (2y2);mTg neonates, with Ki-67 antiserum as the marker of cell
proliferation. (B) Immunocytochemistry of pancreas sections from neonatal wild-type mice, showing the highest levels of PBX-1 (green) in ductal cells (D),
followed by islet cells. Acinar cells stain weakly for PBX-1. Insulin immunostaining (red) is overlaid to indicate the islet. (C) Immunohistochemical detection of
insulin (Left), glucagon (Middle), and somatostatin (Right) cells (arrowheads) within the pancreatic ductal epithelium of neonatal pdx-1 (2y2);mTg mice. Mice
of all other genotypes did not show hormone-positive cells within ducts in any sections examined.














dispensable for glucose homeostasis, inasmuch as overexpression of
the mutant PDX-1 transgene rescued glucose intolerance in pdx-1
heterozygotes. Rather, the PBX interaction motif in PDX-1, and
therefore the PDX-1:PBX complex, was essential for the expansion
of each cell type within the developing pancreas. Pancreata from
pdx-1 (2y2);mTg mice were markedly smaller than those of control
littermates, owing in large part to a reduction in cellular prolifer-
ation among all endocrineyexocrine compartments.
Our immunocytochemical analyses indicate that PDX-1:PBX
complexes are likely to form most abundantly in ducts of the
developing pancreas, the sites of presumed islet cell precursors.
Although cellular levels of the PDX-1:PBX heterodimer may be
regulated in part by nuclear translocation of PBX via MeisyPrep
proteins during development (21), PBX-1 protein was exclusively
nuclear, at least in cells of the neonatal pancreas. Rather,
PDX-1:PBX complexes appear to be limited primarily by the
level of cellular PDX-1; although highly expressed in ductal cells
during development, PDX-1 protein is, except for a few cells
(22), undetectable in ducts of the mature pancreas (23). Re-
markably, ductal expression of PDX-1 in adult cells is induced
after islet cell injury (24) or subtotal pancreatectomy (25).
PDX-1:PBX heterodimers may therefore contribute importantly
to ductal cell proliferation and subsequent islet regeneration.
We imagine that the PDX-1:PBX heterodimer acts chiefly to
induce the expression of genes involved in islet neogenesis. Thus
the highly increased number of hormone-positive cells in ducts
of pdx-1 (2y2); mTg mice may reflect in part premature
specification toward the endocrine cell lineage because these
complexes normally maintain the ductal proliferative state.
Alternatively, PDX-1:PBX may induce the expression of certain
genes that are required for the subsequent migration of hormone
positive cells from ducts. In either case, failure of these cells to
migrate from the duct may contribute to the abnormal islet
morphology in pdx-1 (2y2); mTg mice. In this regard, it will be
of interest to identify PDX-1:PBX target genes that function in
this developmental process.
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